| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;118:2166-2173.)
© 2008 American Heart Association, Inc.
Molecular Cardiology |
From the Vascular Medicine Research Unit, Brigham and Womens Hospital and Harvard Medical School, Cambridge, Mass (C.-Y.W., H.-W.W., Y.L., P.-Y.L., J.K.L.), and Second Section of Cardiology, Department of Medicine, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan (C.-Y.W., M.-S.W., I.-C.H., F.-C.L.).
Correspondence to James K. Liao, MD, Brigham and Womens Hospital, 65 Landsdowne St, Room 275, Cambridge, MA 02139. E-mail jliao{at}rics.bwh.harvard.edu
Received May 5, 2008; accepted September 16, 2008.
| Abstract |
|---|
|
|
|---|
Methods and Results— Endothelial cells from Per2m/m mice exhibit increased protein kinase Akt signaling, greater senescence, and impaired vascular network formation and proliferation. Indeed, Per2m/m mice have impaired blood flow recovery and developed autoamputation of the distal limb when subjected to hind-limb ischemia. Furthermore, matrigel implantation into Per2m/m mice resulted in less neovascularization. Because EPCs contribute to angiogenesis, we studied the role of Per2 in these cells using bone marrow transplantation. Basal EPC levels were similar between wild-type and Per2m/m mice. However, compared with wild-type bone marrow transplantation mice, EPC mobilization was impaired in Per2m/m bone marrow transplantation mice in response to ischemia or VEGF stimulation. Bone marrow transplantation or infusion of wild-type EPC restored blood flow recovery and prevented autoamputation in Per2m/m mice.
Conclusion— These findings indicate that mutation of Per2 causes Akt-dependent senescence and impairs ischemia-induced revascularization through the alteration of EPC function.
Key Words: angiogenesis circadian rhythm endothelium ischemia senescence
| Introduction |
|---|
|
|
|---|
.14 In the cardiovascular system, the production of nitric oxide (NO) and vasoactive prostaglandins is altered in Per2m/m mice.6 However, the vascular consequences of Per2 mutation on NO-mediated angiogenesis and the underlying mechanism responsible for the phenotype have not been investigated or characterized in Per2m/m mice.
Clinical Perspective p 2173
Cardiovascular risks and disease occur at much higher rates in individuals with advanced age and vascular senescence. Vascular senescence as defined by a state of irreversible growth arrest, expression of negative regulators of cell cycle (such as p53 and p16), and increased senescence-related β-galactosidase staining is an important indicator of vascular dysfunction.18,19 Vascular senescence is associated with atherosclerosis,20 endothelial dysfunction,21 increased reactive oxygen species,22 and alteration of telomerase activity.23 However, the precise mechanisms contributing to vascular senescence are not known. We hypothesize that alteration of circadian rhythm leads to vascular senescence, decreased NO bioavailability, and impaired angiogenesis. Using Per2m/m mice, we investigated the effects of Per2 mutation on vascular senescence and the angiogenic response to distal limb ischemia.
| Methods |
|---|
|
|
|---|
Cumulative Population Doublings and Senescence Stain
The lung and aortic endothelial cells were passaged every 3 to 4 days. Cumulative population doubling at each passage was calculated from the cell count with the following equation:24
|
|
where N1 is the inoculum number, NH is the cell harvest number, and X is population doublings. The population doublings were added to yield cumulative population doubling. Replicative senescence is defined as X<1 for 3 weeks. Senescence-associated β-galactosidase staining was performed as previous described at pH 5.5.25
Statistical Analysis
Results are expressed as mean±SEM. Differences between 2 groups were examined by the Student t test. Laser Doppler perfusion images were analyzed with repeated-measures ANOVA with posthoc analysis.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
| Results |
|---|
|
|
|---|
|
Per2 Mutation Leads to Vascular Senescence
To determine whether mutation of Per2 leads to senescence, endothelial cells from WT and Per2m/m mice were subjected to serial passages to test for replicative capacity. WT endothelial cell cultures undergo growth arrest after 10 to 12 passages (Figure 2A). However, Per2m/m endothelial cells exhibited earlier growth arrest at passages 8 to 10. Similar results were obtained from 4 independent Per2m/m and 2 independent WT endothelial cell cultures. To determine whether endothelial cells from Per2m/m mice show increased senescence compared with WT mice, the aortas from 12-month-old mice were stained for senescence-related β-galactosidase activity. The aortas from Per2m/m mice showed increased β-galactosidase staining compared with WT aortas (Figure 2B). When endothelial cells from 12-month-old Per2m/m mice were isolated, they also showed an increased percentage of β-galactosidase-stained cells compared with WT mice (Per2m/m, 74±22%; WT, 12±13%; n=6; P<0.05) (Figure 2C). Furthermore, the expression of endothelin-1, plasminogen activator inhibitor-1, thromboxane A2, hypoxia inducible factor-1
, and vascular endothelial growth factor (VEGF) in endothelial cells from WT and Per2m/m mice was not different (data not shown). These findings indicate that Per2 mutation is associated with increased endothelial cell senescence.
|
Increased Akt Signaling in Per2m/m Mice
The Per2m/m mice have a shortened lifespan and are prone to developing teratomas and lymphomas.14 Furthermore, their thymocytes are relatively resistant to apoptosis in response to
-radiation. Because oncogenesis and senescence have been shown to be associated,26 they are sometimes regulated by similar signaling pathways. We investigated whether Per2 could regulate an oncogene that could be responsible for cellular senescence. We postulate that protein kinase B/Akt, which was initially found to be an oncogene in murine thymic lymphomas, mediates vascular senescence. Compared with endothelial cells from WT mice, endothelial cells from Per2m/m mice exhibited high constitutive levels of Akt Ser473 phosphorylation (pAkt; Figure 3A and 3B). Treatment with VEGF increased pAkt levels in WT endothelial cells but not in Per2m/m endothelial cells (Figure 3A and 3B). Similarly, aortas from Per2m/m mice have 2-times-higher pAkt levels and >50% lower p27 levels (Figure 3C and 3D).
|
Because Akt phosphorylation is regulated by phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin-rictor pathway,27 we examined whether these 2 pathways are altered in Per2m/m mice. Compared with WT mice, the protein levels of mammalian target of rapamycin components, rictor, raptor, and p70 S6 kinase, were not different in Per2m/m mouse aorta (data not shown). Treatment with the PI3K inhibitors LY294002 (LY) and wortmannin decreased pAkt levels in both WT and Per2m/m endothelial cells (Figure 3E), suggesting that constitutive pAkt in Per2m/m mice is due in part to chronic PI3K activation. However, both phosphatase and tensin homolog (P=0.04) and protein phosphatase 2A (P=0.014), which negatively regulate Akt phosphorylation, showed compensatory increases in Per2m/m mice. In contrast, the levels of phosphatidylinositol-dependent kinase-1 (PDK1) in Per2m/m mice are
2.3 times higher than those of WT mice (Figure 3F). These findings suggest that increased PDK1/Akt signaling in Per2m/m mice may contribute to the observed increase in vascular senescence.
Decreased Angiogenesis in Per2m/m Mice
Because Per2m/m mice exhibit endothelial dysfunction6 and senescence, we investigated whether angiogenic function in Per2m/m mice is altered. To study the angiogenic response in vivo, we performed subcutaneous implantation of matrigel with or without VEGF. The matrigel was removed 5 days after implantation, and the incorporated hemoglobin, which correlates with vessel formation, was then quantified. Compared with WT mice, the hemoglobin content of the matrigel was reduced in the Per2m/m mice in the absence of VEGF (Per2m/m, 33±7%; WT, 100±17%; n=6; P<0.05) (Figure 4A and 4B). Although treatment with VEGF produced a similar induction of hemoglobin content in matrigel implanted into WT and Per2m/m mice, the absolute amount of hemoglobin content was substantially less in Per2m/m mice compared with that of WT mice (Per2m/m, 145±11%; WT, 313.6±33%; n=6; P<0.05). These findings indicate that Per2 mutation leads to impaired angiogenesis in vivo.
|
To determine the in vivo relevance of Per2 mutation in postnatal ischemia-induced neovascularization, we performed hind-limb ischemia in WT and Per2m/m mice. Surprisingly, all Per2m/m mice developed autoamputation following hind-limb ischemia after 2 weeks, whereas none of the WT mice developed autoamputation (Figure 5A). This correlated with impaired blood flow recovery after ischemia in Per2m/m mice compared with WT mice after 1 week (Figure 5B). These findings indicate that the circadian gene, Per2, is essential for postischemic blood flow recovery in adult mice.
|
Because bone marrow (BM) cells may contribute to ischemia-induced revascularization, we investigated the role of Per2 mutation in BM-derived endothelial progenitor cells (EPCs). We first investigated EPC levels in WT and Per2m/m mice. EPCs were characterized by positive staining for acetylated low-density lipoprotein, lectin, and endothelial NO synthase.28 Interestingly, there were no significant differences in the baseline EPC levels between WT and Per2m/m mice (Per2m/m, 21±11 per high-power field [hpf]; WT, 20±13 per hpf; n=9; P>0.05). Furthermore, the ability of EPCs from Per2m/m mice to proliferate in vitro was not different compared with that of EPCs from WT mice (data not shown). However, 5 days after hind-limb ischemia, the increase in EPC was substantially less in Per2m/m mice compared with WT mice (Per2m/m, 31±6 per hpf; WT, 51±13 per hpf; n=9; P<0.05) (Figure 5C). To further characterize the EPC response, we administered VEGF165 (500 µg · kg–1 · d–1 SC for 3 days) to WT and Per2m/m mice. The increase in EPC numbers in Per2m/m mice was much less compared with EPC numbers in WT mice (Per2m/m, 43±16 per hpf; WT, 65±12 per hpf; n=9; P<0.05) (Figure 5C).
Mutation of Per2 in BM-Derived Cells Impairs Angiogenesis
To determine the role of Per2 in ischemia-induced neovascularization, we performed BM transplantation (BMT) from WT or Per2m/m mice into irradiated recipient WT mice. Four weeks after BMT, the number of BM-derived EPCs was similar in the 2 groups of recipient mice (Per2m/m, 17±9 per hpf; WT, 16±12 per hpf; n=6; P=0.25), and hind-limb ischemia was then induced. Compared with mice receiving WT BM (WT
WT BMT mice), Per2m/m
WT BMT mice exhibited 27±0.9% less blood flow recovery at 28 days after surgery (Figure 6A and 6B). The microcapillary density in the ischemic adductor skeletal muscle tissue also was substantially less in Per2m/m
WT BMT mice compared with WT
WT BMT mice (Per2m/m
WT, 1543±652/mm2; WT
WT, 2542±523/mm2; n=6; P<0.05) (Figure 6C). These findings suggest that mutation of Per2 in BM-derived cells impairs ischemia-induced neovascularization.
|
To determine whether infusion of WT EPCs rather than BMT can restore the angiogenic response and prevent the autoamputation observed in Per2m/m mice after hind-limb ischemia, we infused EPCs (2x105 cells) from either WT or Per2m/m mice into recipient Per2m/m mice and then monitored these mice (WT
Per2m/m and Per2m/m
Per2m/m mice) for blood flow recovery and autoamputation. Surprisingly, the autoamputation phenotype was completely rescued in both groups of mice (Figure 6D and 6E). However, consistent with our findings, the Per2m/m mice receiving EPCs from Per2m/m mice showed less blood flow recovery compared with mice receiving EPCs from WT mice (Per2m/m
Per2m/m, 34±6%; WT
Per2m/m, 61±15%; n=6; P<0.05). Quantitative histological analysis of neovascularization revealed that capillary density was lower in the ischemic adductor muscle of Per2m/m mice receiving EPCs from Per2m/m mice compared with similar mice receiving EPCs from WT mice (Per2m/m
Per2m/m, 1298± 118/mm2; WT
Per2m/m, 1762±661/mm2; n=6; P<0.05) (Figure 6F). Taken together, our findings indicate that the autoamputation observed in Per2m/m mice could be rescued by intravenous infusion of EPCs from either WT or Per2m/m mice but that, in contrast to EPCs from Per2m/m mice, only EPCs from WT mice have the ability to restore ischemia-induced neovascularization and blood flow recovery in Per2m/m mice. These findings strongly suggest that Per2 in BM-derived cells, particularly in EPCs, mediates ischemia-induced revascularization.
Inhibition of Akt Signaling Rescues the Impairment of Cellular Function in Per2m/m Mice
Next, we examined whether inhibition or knockdown of excessive Akt signaling could restore and improve endothelial function such as proliferation or vascular network formation in Per2m/m mice. Akt1 is the predominant isoform in endothelium, and Akt1 haploinsufficiency leads to less Akt activation.29 Because Akt1 also mediates tumor and ischemic angiogenesis,30 we investigated the role of Akt1 in Per2m/m mice by crossing Per2m/m mice with Akt1–/– mice to generate Per2m/m/Akt1+/– mice. Consistent with previous reports, we found that Akt1+/– mice have less pAkt (Figure 7A). Despite less Akt activity, there were no significant differences in endothelial cell proliferation or vascular network formation between Akt1+/+ and Akt1+/– mice (Figure 7B and 7C). Haploinsufficiency of Akt1, however, restored the impaired vascular network formation and endothelial cell proliferation in Per2m/m mice (Figure 7B and 7C). These findings suggest that excessive Akt activation in Per2m/m mice is probably responsible for the impaired vascular function in these mice.
|
| Discussion |
|---|
|
|
|---|
Decreased replicative capacity refers to a condition when cells lose their ability to replicate after a finite number of cell divisions. Reduced cellular replicative capacity is a marker of senescence and correlates with aging. Although a change in cellular replicative capacity often is associated with aging or senescence, it also is observed sometimes in tumor suppression.26,32,33 In this study, we have shown that endothelial cell senescence as defined by decreased replicative capacity is associated with impaired vascular function and angiogenesis.
Our findings indicate that vascular senescence and dysfunction are associated with chronic upregulation of Akt signaling. Overactivity of Akt has been linked to increased vascular senescence through increased reactive oxygen species generation and decreased NO bioavailability.34 Indeed, excessive Akt activation and impaired angiogenesis are observed in VEGF receptor-1 (VEGFR-1 or flt-1) haploinsufficient mice as a result of unmitigated VEGFR-2 (flk-1/KDR) signaling.35 We find that mutation of Per2 leads to greater Akt phosphorylation via the PI3K-dependent pathway and upregulation of PDK1. PDK1 is an important regulator of insulin and growth factor-stimulated protein kinases such as Akt,36 p70 ribosomal S6 kinase,37 and p90 ribosomal S6 kinase.38 PDK1 also is important in regulating murine development and multiple cellular functions.39 A potential downstream target of PDK1/Akt that may mediate senescence is FOXO. For example, the insulin/PI3K/Akt/FOXO pathway has been shown to alter the lifespans of organisms from worms to mice,40,41 and insulin signaling has been shown to regulate circadian rhythm through FOXO.42 Thus, insulin signaling, aging, and circadian rhythm may be linked through chronic, excessive PDK1/Akt activation. However, further studies are required to determine how Per2 regulates Akt activation through PI3K/PDK1.
We found that mutation of Per2 leads to decreased EPC levels in response to ischemia or VEGF. However, the ability of EPCs from Per2m/m mice to proliferate in vitro was not different compared with that of EPCs from WT mice. These findings suggest that the defect in EPC function in Per2m/m mice is due to EPC mobilization rather than proliferation. This is in agreement with previous studies showing that NO is required for EPC mobilization43 and that NO bioavailability is impaired in Per2m/m mice.6 Furthermore, several studies suggest that the circadian rhythm affects stem cell function.44,45 For example, hematopoiesis and phagocytosis by BM-derived cells have circadian variations.46,47 Thus, disturbances or disruption in circadian genes is likely to affect the function of BM-derived cells, including EPCs. Because Per2 mutation leads to both endothelial senescence and decreased EPC mobilization, both phenotypes may contribute to the autoamputation observed in Per2m/m mice after hind-limb ischemia. Indeed, blood flow recovery after hind-limb ischemia in WT
Per2m/m BMT mice was still substantially lower than that of WT
WT BMT mice (ischemic-to-nonischemic limb ratio, 0.35 versus 0.62), suggesting that impaired intrinsic vascular function, in addition to impaired EPC function, contributes importantly to the altered angiogenic response and autoamputation in Per2m/m mice.
We find that alteration of the circadian rhythm leads to vascular senescence. Although Per2 mutation leads to increased Akt signaling and excessive Akt activation is linked to increased vascular senescence by oxidative stress,34 Akt may not be the only factor that mediates the senescence phenotype. Because Per2m/m mice exhibit a wide array of phenotypic abnormalities, other factors that are downstream of Per2 may cooperate with Akt in causing replicative senescence. These factors may include genes that regulate the cell cycle such as c-myc, p27Kip1, Cyclin D1, and Cyclin A.16 In particular, p27Kip1 is important in cell cycle control, and disruption of the cyclin-dependent kinase-inhibitory domain of p27 enhances growth of mice.48 Disruption of p27 increases cell proliferation, cell cycle progression,49 and senescence, which is compatible to our findings. As mentioned, the decrease in NO bioavailability in Per2m/m mice6 also may contribute to senescence, although senescence itself may ultimately lead to decreased NO bioavailability and endothelial dysfunction. Regardless of the precise mechanism by which mutation of Per2 causes vascular senescence, Per2m/m mice have circadian rhythm disturbances and have impaired EPC function and angiogenic response to limb ischemia. These findings suggest that polymorphisms or alteration of circadian genes may be linked to cardiovascular disease. It remains to be determined, however, whether restoration of circadian gene function could ameliorate age-related vascular diseases.
| Acknowledgments |
|---|
This work was supported in part by grants from the National Institutes of Health (HL052233 and HL080187 to Dr Liao) and Chang Gung Memorial Hospital (CMRPG34016 and CMRPG370811 to Dr Wang).
Disclosures
None.
| References |
|---|
|
|
|---|
2. Akerstedt T, Knutsson A, Alfredsson L, Theorell T. Shift work and cardiovascular disease. Scand J Work Environ Health. 1984; 10: 409–414.[Medline] [Order article via Infotrieve]
3. Knutsson A, Boggild H. Shiftwork and cardiovascular disease: review of disease mechanisms. Rev Environ Health. 2000; 15: 359–372.[Medline] [Order article via Infotrieve]
4. Curtis AM, Cheng Y, Kapoor S, Reilly D, Price TS, Fitzgerald GA. Circadian variation of blood pressure and the vascular response to asynchronous stress. Proc Natl Acad Sci U S A. 2007; 104: 3450–3455.
5. Malik M, Farrell T, Camm AJ. Circadian rhythm of heart rate variability after acute myocardial infarction and its influence on the prognostic value of heart rate variability. Am J Cardiol. 1990; 66: 1049–1054.[CrossRef][Medline] [Order article via Infotrieve]
6. Viswambharan H, Carvas JM, Antic V, Marecic A, Jud C, Zaugg CE, Ming XF, Montani JP, Albrecht U, Yang Z. Mutation of the circadian clock gene Per2 alters vascular endothelial function. Circulation. 2007; 115: 2188–2195.
7. Tofler GH, Brezinski D, Schafer AI, Czeisler CA, Rutherford JD, Willich SN, Gleason RE, Williams GH, Muller JE. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987; 316: 1514–1518.[Abstract]
8. Panza JA, Epstein SE, Quyyumi AA. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med. 1991; 325: 986–990.[Abstract]
9. Reilly DF, Westgate EJ, FitzGerald GA. Peripheral circadian clocks in the vasculature. Arterioscler Thromb Vasc Biol. 2007; 27: 1694–1705.
10. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002; 418: 935–941.[CrossRef][Medline] [Order article via Infotrieve]
11. Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, Laposky A, Losee-Olson S, Easton A, Jensen DR, Eckel RH, Takahashi JS, Bass J. Obesity and metabolic syndrome in circadian Clock mutant mice. Science. 2005; 308: 1043–1045.
12. Kondratov RV, Kondratova AA, Gorbacheva VY, Vykhovanets OV, Antoch MP. Early aging and age-related pathologies in mice deficient in BMAL1, the core component of the circadian clock. Genes Dev. 2006; 20: 1868–1873.
13. Wisor JP, O'Hara BF, Terao A, Selby CP, Kilduff TS, Sancar A, Edgar DM, Franken P. A role for cryptochromes in sleep regulation. BMC Neurosci. 2002; 3: 20.[CrossRef][Medline] [Order article via Infotrieve]
14. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002; 111: 41–50.[CrossRef][Medline] [Order article via Infotrieve]
15. Lee CC. Tumor suppression by the mammalian Period genes. Cancer Causes Control. 2006; 17: 525–530.[CrossRef][Medline] [Order article via Infotrieve]
16. Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G. The molecular clock mediates leptin-regulated bone formation. Cell. 2005; 122: 803–815.[CrossRef][Medline] [Order article via Infotrieve]
17. Spanagel R, Pendyala G, Abarca C, Zghoul T, Sanchis-Segura C, Magnone MC, Lascorz J, Depner M, Holzberg D, Soyka M, Schreiber S, Matsuda F, Lathrop M, Schumann G, Albrecht U. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med. 2005; 11: 35–42.[CrossRef][Medline] [Order article via Infotrieve]
18. Erusalimsky JD, Fenton M. Further in vivo evidence that cellular senescence is implicated in vascular pathophysiology. Circulation. 2002; 106: e144.[CrossRef][Medline] [Order article via Infotrieve]
19. Minamino T, Yoshida T, Tateno K, Miyauchi H, Zou Y, Toko H, Komuro I. Ras induces vascular smooth muscle cell senescence and inflammation in human atherosclerosis. Circulation. 2003; 108: 2264–2269.
20. Minamino T, Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ Res. 2007; 100: 15–26.
21. Kunieda T, Minamino T, Katsuno T, Tateno K, Nishi J, Miyauchi H, Orimo M, Okada S, Komuro I. Cellular senescence impairs circadian expression of clock genes in vitro and in vivo. Circ Res. 2006; 98: 532–539.
22. Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation. 2004; 110: 856–861.
23. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci U S A. 1995; 92: 11190–11194.
24. Cristofalo VJ, Allen RG, Pignolo RJ, Martin BG, Beck JC. Relationship between donor age and the replicative lifespan of human cells in culture: a reevaluation. Proc Natl Acad Sci U S A. 1998; 95: 10614–10619.
25. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995; 92: 9363–9367.
26. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004; 432: 307–315.[CrossRef][Medline] [Order article via Infotrieve]
27. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129: 1261–1274.[CrossRef][Medline] [Order article via Infotrieve]
28. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999; 5: 434–438.[CrossRef][Medline] [Order article via Infotrieve]
29. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, Kadowaki T, Hay N. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 2001; 15: 2203–2208.
30. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res. 2002; 90: 1243–1250.
31. Monk TH. Aging human circadian rhythms: conventional wisdom may not always be right. J Biol Rhythms. 2005; 20: 366–374.
32. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005; 436: 725–730.[CrossRef][Medline] [Order article via Infotrieve]
33. Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C, Flores JM, Vina J, Blasco MA, Serrano M. Delayed ageing through damage protection by the Arf/p53 pathway. Nature. 2007; 448: 375–379.[CrossRef][Medline] [Order article via Infotrieve]
34. Miyauchi H, Minamino T, Tateno K, Kunieda T, Toko H, Komuro I. Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J. 2004; 23: 212–220.[CrossRef][Medline] [Order article via Infotrieve]
35. Nishi JI, Minamino T, Miyauchi H, Nojima A, Tateno K, Okada S, Orimo M, Moriya J, Fong GH, Sunagawa K, Shibuya M, Komuro I. Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt. Circ Res. 2008; 103: 261–268.
36. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci. 2001; 26: 657–664.[CrossRef][Medline] [Order article via Infotrieve]
37. Avruch J, Belham C, Weng Q, Hara K, Yonezawa K. The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. Prog Mol Subcell Biol. 2001; 26: 115–154.[Medline] [Order article via Infotrieve]
38. Frodin M, Jensen CJ, Merienne K, Gammeltoft S. A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1. EMBO J. 2000; 19: 2924–2934.[CrossRef][Medline] [Order article via Infotrieve]
39. Lawlor MA, Mora A, Ashby PR, Williams MR, Murray-Tait V, Malone L, Prescott AR, Lucocq JM, Alessi DR. Essential role of PDK1 in regulating cell size and development in mice. EMBO J. 2002; 21: 3728–3738.[CrossRef][Medline] [Order article via Infotrieve]
40. Bluher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science. 2003; 299: 572–574.
41. Lin K, Dorman JB, Rodan A, Kenyon C. daf-16: An HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans. Science. 1997; 278: 1319–1322.
42. Zheng X, Yang Z, Yue Z, Alvarez JD, Sehgal A. FOXO and insulin signaling regulate sensitivity of the circadian clock to oxidative stress. Proc Natl Acad Sci U S A. 2007; 104: 15899–15904.
43. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003; 9: 1370–1376.[CrossRef][Medline] [Order article via Infotrieve]
44. Tsinkalovsky O, Smaaland R, Rosenlund B, Sothern RB, Hirt A, Steine S, Badiee A, Abrahamsen JF, Eiken HG, Laerum OD. Circadian variations in clock gene expression of human bone marrow CD34+ cells. J Biol Rhythms. 2007; 22: 140–150.
45. Tsinkalovsky O, Filipski E, Rosenlund B, Sothern RB, Eiken HG, Wu MW, Claustrat B, Bayer J, Levi F, Laerum OD. Circadian expression of clock genes in purified hematopoietic stem cells is developmentally regulated in mouse bone marrow. Exp Hematol. 2006; 34: 1249–1261.[Medline] [Order article via Infotrieve]
46. Smaaland R, Sothern RB, Laerum OD, Abrahamsen JF. Rhythms in human bone marrow and blood cells. Chronobiol Int. 2002; 19: 101–127.[CrossRef][Medline] [Order article via Infotrieve]
47. D'Hondt L, McAuliffe C, Damon J, Reilly J, Carlson J, Dooner M, Colvin G, Lambert JF, Hsieh CC, Habibian H, Stencel K, Quesenberry PJ. Circadian variations of bone marrow engraftability. J Cell Physiol. 2004; 200: 63–70.[CrossRef][Medline] [Order article via Infotrieve]
48. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 1996; 85: 721–732.[CrossRef][Medline] [Order article via Infotrieve]
49. Lowenheim H, Furness DN, Kil J, Zinn C, Gultig K, Fero ML, Frost D, Gummer AW, Roberts JM, Rubel EW, Hackney CM, Zenner HP. Gene disruption of p27(Kip1) allows cell proliferation in the postnatal and adult organ of corti. Proc Natl Acad Sci U S A. 1999; 96: 4084–4088.
| Footnotes |
|---|
The online-only Data Supplement can be found with this article at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.108.790469/DC1.
Related Article:
Circulation 2008 118: 2115-2116.
This article has been cited by other articles:
![]() |
R. D. Rudic Time Is of the Essence: Vascular Implications of the Circadian Clock Circulation, October 27, 2009; 120(17): 1714 - 1721. [Full Text] [PDF] |
||||
![]() |
R. D. Rudic and D. J. Fulton Pressed for time: the circadian clock and hypertension J Appl Physiol, October 1, 2009; 107(4): 1328 - 1338. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhao, S. G. Thacker, J. B. Hodgin, H. Zhang, J. H. Wang, J. L. Park, A. Randolph, E. C. Somers, S. Pennathur, M. Kretzler, et al. The Peroxisome Proliferator-Activated Receptor {gamma} Agonist Pioglitazone Improves Cardiometabolic Risk and Renal Inflammation in Murine Lupus J. Immunol., August 15, 2009; 183(4): 2729 - 2740. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-Y. Wang, H.-H. Kim, Y. Hiroi, N. Sawada, S. Salomone, L. E. Benjamin, K. Walsh, M. A. Moskowitz, and J. K. Liao Obesity Increases Vascular Senescence and Susceptibility to Ischemic Injury Through Chronic Activation of Akt and mTOR Sci. Signal., March 17, 2009; 2(62): ra11 - ra11. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |